---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-25T13:56:41.629202'
end_time: '2026-09-25T14:56:46.981765'
duration_seconds: 3605.35
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Roberts Syndrome
  mondo_id: MONDO:0100253
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 12
reference_validation:
  total_references: 16
  verified: 16
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 16
  on_topic: 15
  validator_version: 0.3.0rc1
term_validation:
  total_terms: 38
  verified: 35
  not_found: 0
  obsolete: 0
  unverifiable: 3
  confabulation_rate: 0.0
  labels_checked: 21
  labels_matching: 15
  labels_mismatched: 5
  mislabelled_terms:
  - term_id: CHEBI:15603
    reported_labels:
    - L-leucine
    - Mechanism-based experimental lead:** **L-leucine
    ontology_label: L-leucine
  - term_id: HP:0000252
    reported_labels:
    - Common
    ontology_label: Microcephaly
  - term_id: HP:0001249
    reported_labels:
    - "Mild\u2013severe, variable"
    ontology_label: Intellectual disability
  - term_id: HP:0012165
    reported_labels:
    - Common
    ontology_label: Oligodactyly
  - term_id: HP:0003826
    reported_labels:
    - Severe forms
    ontology_label: Stillbirth
  labels_variant: 1
  unresolvable_prefixes:
  - ORPHA
  - OMIM
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Roberts_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Roberts_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Roberts Syndrome
- **MONDO ID:** MONDO:0100253 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Roberts Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Roberts Syndrome (RBS): A Comprehensive Disease Characteristics Report

**MONDO:** MONDO:0100253 · **OMIM:** #268300 · **Orphanet:** ORPHA:3103 · **MeSH/UMLS:** C0392475 · **Gene:** *ESCO2* (8p21.1; OMIM \*609353; HGNC:24645) · **Category:** Mendelian, autosomal-recessive cohesinopathy

---

## Summary

**Roberts syndrome (RBS)**, including its milder allelic form **SC phocomelia**, is a rare autosomal-recessive developmental disorder caused by **biallelic loss-of-function mutations in *ESCO2*** (Establishment of Sister Chromatid Cohesion N-Acetyltransferase 2) on chromosome **8p21.1**. ESCO2 is a zinc-finger/Gcn5-like acetyltransferase that acetylates the cohesin subunit **SMC3** to establish sister-chromatid cohesion during S phase. When ESCO2 activity is lost, centromeric cohesion fails — producing the pathognomonic cytogenetic hallmarks of **premature centromere separation (PCS)** and **heterochromatin repulsion (HR)** — and the developing embryo cannot sustain the rapid, faithful cell divisions required for limb, craniofacial, and somatic growth. The clinical result is a triad of **symmetric limb reduction (up to tetraphocomelia)**, **pre- and postnatal growth retardation**, and **craniofacial anomalies**, frequently accompanied by microcephaly and variable intellectual disability.

The molecular pathogenesis converges through at least **four downstream branches**: (1) mitotic failure and apoptosis of proliferating progenitor cells; (2) DNA-damage and redox stress; (3) nucleolar fragmentation with impaired ribosome biogenesis and depressed **mTORC1-dependent translation**; and (4) cohesin-dependent transcriptional dysregulation, including regulation of the **CRL4 ubiquitin ligase**. A notable, mechanism-based therapeutic lead is **L-leucine**, an mTORC1 stimulator that partially rescues translation and development in RBS cell and zebrafish models.

Clinically, RBS shows **highly variable expressivity with no genotype–phenotype correlation** — from severe forms with perinatal/stillbirth lethality to milder SC phocomelia compatible with survival into adulthood. Diagnosis rests on characteristic clinical features, the cytogenetic PCS/HR signature, and confirmatory *ESCO2* sequencing; prenatal diagnosis is feasible by serial fetal ultrasound with long-bone measurement and by molecular testing in known families. No curative therapy exists; management is supportive, reconstructive, and rehabilitative, supported by genetic counseling.

---

## Key Findings

### F001 — Roberts syndrome is caused by biallelic loss-of-function mutations in *ESCO2* (8p21.1)

Multiple independent case series establish that RBS and SC phocomelia result from **biallelic, protein-truncating mutations** (frameshift, nonsense, splice-site) in *ESCO2*. Schüle et al. identified seven novel mutations across exons 3–8, all protein-truncating regardless of clinical severity. The gene product, **ESCO2 (Establishment of Sister Chromatid Cohesion N-Acetyltransferase 2)**, maps to **8p21.1**.

- [PMID: 16380922](https://pubmed.ncbi.nlm.nih.gov/16380922/): *"Recently, mutations in ESCO2 (establishment of cohesion 1 homolog 2) on 8p21.1 have been reported in RBS."*
- [PMID: 16380922](https://pubmed.ncbi.nlm.nih.gov/16380922/): *"Since only protein-truncating mutations were identified, regardless of clinical severity, we conclude that genotype does not predict phenotype."*
- [PMID: 32783269](https://pubmed.ncbi.nlm.nih.gov/32783269/): *"Biallelic loss-of-function variants in ESCO2, which codes for establishment of sister chromatid cohesion N-acetyltransferase 2, cause Roberts syndrome."*

**Ontology suggestions:** Gene HGNC:24645 (*ESCO2*); MONDO:0100253; OMIM:268300.

### F002 — RBS and SC phocomelia are allelic with no genotype–phenotype correlation

Schüle et al. (2005) studied three SC phocomelia families plus two families with variable limb/craniofacial abnormalities; **all** were positive for heterochromatin repulsion and **all** carried truncating *ESCO2* mutations, demonstrating that RBS and SC phocomelia are caused by mutations in the **same gene**. An Egyptian cohort of eight patients independently confirmed the absence of genotype–phenotype correlation. This allelism and variable expressivity are central to genetic counseling and prognosis.

- [PMID: 16380922](https://pubmed.ncbi.nlm.nih.gov/16380922/): *"Having established that RBS and SC are caused by mutations"*
- [PMID: 30204960](https://pubmed.ncbi.nlm.nih.gov/30204960/): *"We confirmed previous results of lack of genotype/phenotype correlation."*

### F003 — Cytogenetic hallmark: premature centromere separation / heterochromatin repulsion

Patient metaphase spreads show **premature centromere separation (PCS)**, **heterochromatin repulsion (HR)** — the classic "railroad track"/puffing appearance at heterochromatic centromeric and Y chromosome regions — and **chromosome breaks**, visualized by Giemsa, DAPI, and C-banding. HR is consistently present in both RBS and SC phocomelia and is used as a diagnostic marker.

- [PMID: 32783269](https://pubmed.ncbi.nlm.nih.gov/32783269/): *"characteristic cytogenetic defects, such as premature centromere separation, heterochromatin repulsion, and chromosome breaks, in patient cells strongly supported pathogenicity"*
- [PMID: 30204960](https://pubmed.ncbi.nlm.nih.gov/30204960/): *"Cytogenetic studies including centromeric separation and puffing by Giemsa and DAPI stains"*

### F004 — ESCO2 loss disrupts the cell cycle and triggers apoptosis in developing tissues

A **zebrafish** *esco2* knockdown model recapitulates RBS, including **mitotic defects, craniofacial abnormalities, and limb truncations**. Microarray analysis showed that Esco2-regulated genes are enriched for **cell cycle and apoptosis** functions — distinct from the targets of the core cohesin subunit rad21, which enriched for transcriptional regulators. This positions cell-cycle disruption and programmed cell death of proliferating progenitors as a key downstream mechanism linking cohesion failure to tissue hypoplasia.

- [PMID: 21637801](https://pubmed.ncbi.nlm.nih.gov/21637801/): *"Esco2 depleted zebrafish embryos exhibit features that resemble RBS, including mitotic defects, craniofacial abnormalities and limb truncations."*
- [PMID: 21637801](https://pubmed.ncbi.nlm.nih.gov/21637801/): *"Esco2-regulated genes were more likely to be involved the cell cycle or apoptosis"*

**Ontology suggestions:** GO:0007049 (cell cycle); GO:0006915 (apoptotic process); GO:0007062 (sister chromatid cohesion).

### F005 — ESCO2/cohesin loss produces DNA damage and redox stress

In *Saccharomyces cerevisiae* RBS models (*eco1* mutants, homologous to human *ESCO2*), **redox stress is elevated**, oxidative-DNA-damage repair is impaired, and DNA-damage checkpoints are hyperactivated. Critically, **antioxidant treatment desensitizes *eco1* cells** to DNA-damaging agents, supporting an oxidative-stress/DNA-damage arm of pathogenesis and hinting at an antioxidant intervention strategy. A complementary "macromolecular damage" model broadens the injury beyond DNA to include translational/ribosomal machinery.

- [PMID: 34897432](https://pubmed.ncbi.nlm.nih.gov/34897432/): *"the results reveal that redox stress is elevated in both eco1 and cohesion factor Saccharomyces cerevisiae mutant cells"*
- [PMID: 34897432](https://pubmed.ncbi.nlm.nih.gov/34897432/): *"antioxidant treatment desensitizes eco1 mutant cells to a range of DNA damaging agents"*

**Ontology suggestions:** GO:0006979 (response to oxidative stress); GO:0006281 (DNA repair).

### F006 — Nucleolar fragmentation, impaired ribosome biogenesis, and depressed mTORC1 translation — rescued by L-leucine

RBS cells display **highly fragmented nucleoli** with defects in **ribosome biogenesis** (rRNA/snoRNA production) and reduced overall protein translation; **mTORC1 signaling is depressed**. Treatment with **L-leucine**, an mTORC1 stimulator, partially rescues mTOR function, translational efficiency of ribosomal subunits and initiation factors, mitochondrial function, cell division, and development in both RBS cells and zebrafish models. The same translational axis operates across cohesinopathies (e.g., Cornelia de Lange syndrome, CdLS). This is the most concrete **mechanism-based therapeutic lead** for RBS.

- [PMID: 26729373](https://pubmed.ncbi.nlm.nih.gov/26729373/): *"mTORC1 signaling was depressed and overall translation was reduced in RBS cells and zebrafish models for RBS. Treatment of RBS cells and zebrafish RBS models with L-leucine partially rescued mTOR function and protein synthesis, correlating with increased cell division and improved development."*
- [PMID: 25378554](https://pubmed.ncbi.nlm.nih.gov/25378554/): *"RBS was associated with highly fragmented nucleoli and defects in both ribosome biogenesis and protein translation. l-leucine stimulation of the mTOR pathway partially rescued translation in human RBS cells and development in zebrafish models of RBS."*

**Ontology suggestions:** GO:0042254 (ribosome biogenesis); GO:0006412 (translation); GO:0031929 (TOR signaling); GO:0005730 (nucleolus); CHEBI:15603 (L-leucine).

### F007 — Recurrent frameshift/truncating alleles cluster in exon 3; prenatal diagnosis is feasible

The Egyptian cohort (Afifi et al., 2016) reported **homozygous exon-3 frameshift mutations**, including the novel **c.244_245dupCT (p.T83Pfs\*20)** and previously reported **c.760_761insA (p.T254Nfs\*27)** and **c.764_765delTT (p.F255Cfs\*25)**. All patients showed growth retardation, mesomelic limb shortening (upper > lower limbs), microcephaly, and characteristic PCS with heterochromatin puffing. **Serial fetal ultrasound with long-bone measurement diagnosed two affected fetuses prenatally**, and severity of mesomelic shortening and craniofacial anomalies varied among patients (variable expressivity).

- [PMID: 26710928](https://pubmed.ncbi.nlm.nih.gov/26710928/): *"sequencing of the ESCO2 gene identified a novel mutation c.244_245dupCT (p.T83Pfs*20) in one family besides two previously reported mutations c.760_761insA (p.T254Nfs*27) and c.764_765delTT (p.F255Cfs*25). All mutations were in homozygous state, in exon 3."*
- [PMID: 26710928](https://pubmed.ncbi.nlm.nih.gov/26710928/): *"Serial fetal ultrasound examinations and measurements of long bones diagnosed two affected fetuses in two of the studied families."*
- [PMID: 26710928](https://pubmed.ncbi.nlm.nih.gov/26710928/): *"The severity of the mesomelic shortening of the limbs and craniofacial anomalies showed variability among patients."*

### F008 — ESCO2 is a zinc-finger/Gcn5-like acetyltransferase; missense variants cause RBS (germline) and occur in cancers (somatic)

X-ray crystallography of the conserved zinc-finger–acetyltransferase moiety of the ESCO paralog **ESCO1** shows that the catalytic core is **structurally homologous to the Gcn5 histone acetyltransferase (HAT)**, with a unique zinc finger and an ~40-residue loop that mediate protein stability and **SMC3 substrate binding**. **Missense mutations in the acetyltransferase domain correlate with disease** — Roberts syndrome (germline) and endometrial cancers (somatic) — linking RBS mechanistically to genome-instability phenotypes seen in cancer.

- [PMID: 27803161](https://pubmed.ncbi.nlm.nih.gov/27803161/): *"Missense mutations within the acetyltransferase domain of these proteins correlate with diseases, including endometrial cancers and Roberts syndrome."*
- [PMID: 27803161](https://pubmed.ncbi.nlm.nih.gov/27803161/): *"the ESCO1 acetyltransferase core is structurally homologous to the Gcn5 HAT, but contains unique additional features including a zinc finger and an ∼40-residue loop region that appear to play roles in protein stability and SMC3 substrate binding"*

**Ontology suggestions:** GO:0016407 (acetyltransferase activity); GO:0008270 (zinc ion binding); UniProt Q56NI9 (ESCO2_HUMAN).

---

## Section-by-Section Report

### 1. Disease Information

Roberts syndrome is a rare, autosomal-recessive multiple-congenital-anomaly disorder characterized by **symmetric limb reduction defects, growth retardation, and craniofacial anomalies**. It exists on a clinical severity spectrum with **SC phocomelia** (formerly "pseudothalidomide syndrome"), now known to be allelic (same gene, *ESCO2*) (F001, F002).

**Key identifiers:** MONDO:0100253; OMIM #268300; Orphanet ORPHA:3103; MeSH/UMLS C0392475; ICD-10 Q87.8 (no dedicated code); ICD-11 within multiple-congenital-anomaly syndromes. Gene: *ESCO2*, HGNC:24645, 8p21.1.

**Synonyms/alternative names:** Roberts–SC phocomelia syndrome; SC phocomelia syndrome; pseudothalidomide syndrome; hypomelia–hypotrichosis–facial hemangioma syndrome; Appelt–Gerken–Lenz syndrome; RBS.

**Information source:** Predominantly **aggregated disease-level resources** (OMIM, Orphanet) and **individual patient case reports/small cohorts** (Egyptian cohort of 8 patients; Indian and Nigerian case reports). There is no large EHR-derived dataset; the disorder's rarity means knowledge derives from curated literature.

### 2. Etiology

**Primary cause — genetic:** Biallelic (homozygous or compound heterozygous) **loss-of-function mutations in *ESCO2*** (F001). Nearly all reported alleles are protein-truncating; recurrent frameshift alleles cluster in **exon 3** (F007).

**Genetic risk factors:** The disorder is monogenic and fully determined by biallelic *ESCO2* LoF; **consanguinity** is a major risk factor because it increases homozygosity for rare recessive alleles (predominance of homozygous cases in consanguineous populations, F007). No common susceptibility loci or polygenic contribution.

**Environmental/lifestyle risk factors:** None established. RBS is not caused by environmental exposure. (Historically confused with thalidomide embryopathy — hence "pseudothalidomide" — reflecting phenotypic mimicry, not shared etiology.)

**Protective factors:** No genetic or environmental protective factors are established. Mechanistically, **L-leucine** (mTORC1 stimulation) and **antioxidants** are experimental modifiers of cellular phenotype (F005, F006), not population-level protective factors.

**Gene–environment interactions:** None documented for causation. The only "interaction" of note is experimental therapeutic modulation (leucine/antioxidants) of the mutant cellular phenotype.

### 3. Phenotypes

RBS phenotypes are **congenital (prenatal onset)**, **bilateral/symmetric**, and range from **mild to severe** with **variable expressivity** (F002, F007).

| Phenotype | Type | Onset | Severity/Frequency | Suggested HPO |
|---|---|---|---|---|
| Symmetric limb reduction / phocomelia / tetraphocomelia | Physical malformation | Congenital | Severe; upper > lower limbs; hallmark | HP:0009829 (phocomelia); HP:0009821 (limb reduction) |
| Pre- and postnatal growth retardation | Clinical sign | Prenatal | Severe; near-universal | HP:0001511 (IUGR); HP:0001510 |
| Microcephaly | Physical sign | Congenital | Common | HP:0000252 |
| Craniofacial anomalies (cleft lip/palate, hypertelorism, micrognathia, malar hypoplasia) | Physical malformation | Congenital | Common, variable | HP:0000175; HP:0000316 |
| Intellectual disability | Behavioral/cognitive | Childhood | Mild–severe, variable | HP:0001249 |
| Oligodactyly / absent digits | Physical malformation | Congenital | Common | HP:0012165 |
| Cardiac / renal / genital anomalies | Structural | Congenital | Variable | HP:0001627; HP:0000119 |
| Sparse/silvery hair, facial hemangioma | Physical sign | Congenital | Reported (SC phocomelia) | HP:0008070; HP:0001028 |
| Stillbirth / early mortality | Outcome | Perinatal | Severe forms | HP:0003826 |

**Quality-of-life impact:** Severe forms are perinatally lethal (stillbirth/early death); survivors face major mobility limitation from limb reduction, need for reconstructive/prosthetic support, and variable cognitive impairment. Formal EQ-5D/SF-36 data are **not available** for this ultra-rare condition.

### 4. Genetic / Molecular Information

**Causal gene:** *ESCO2* (HGNC:24645, OMIM \*609353), 8p21.1, encoding a **zinc-finger/Gcn5-like acetyltransferase** (F001, F008).

**Pathogenic variants:** Predominantly **protein-truncating** — frameshift, nonsense, splice-site (F001). Recurrent exon-3 frameshifts: **c.244_245dupCT (p.T83Pfs\*20)**, **c.760_761insA (p.T254Nfs\*27)**, **c.764_765delTT (p.F255Cfs\*25)** (F007). Rare **missense** variants in the acetyltransferase domain also cause RBS and, somatically, appear in endometrial cancers (F008). ACMG/AMP: LoF truncating variants are typically **pathogenic**; a splice variant in an Indian patient was corroborated by cytogenetic PCS/HR evidence (F003, PMID:32783269).

**Allele frequency:** Causal alleles are rare/private; carrier frequencies are not well quantified in gnomAD given rarity. **Somatic vs germline:** RBS alleles are **germline** and biallelic; ESCO2 missense changes are also found **somatically** in cancers (F008). **Functional consequence:** **loss of function** — loss of SMC3 acetyltransferase activity and failure to establish sister-chromatid cohesion (F008).

**Modifier genes:** No formal human modifiers identified (consistent with no genotype–phenotype correlation, F002). Model-organism work identifies **RAD61/WAPL, PDS5, DDX11, and CRL4/DDB1** as functional interactors. **DDX11** (Warsaw Breakage Syndrome gene) and ESCO2 have non-redundant, partially compensatory roles in cohesion (PMID:31935221).

**Epigenetic information:** ESCO2 acetylates SMC3 (a chromatin-associated protein); cohesin influences chromatin architecture and transcription. No disease-specific DNA-methylation signature is established for RBS.

**Chromosomal abnormalities:** The disease-defining cytogenetic finding is **functional** (PCS/HR, chromosome breaks), not a constitutional large-scale rearrangement (F003).

### 5. Environmental Information

No environmental factors, toxins, radiation, lifestyle factors, or infectious agents are implicated in RBS causation. The disorder is entirely genetic (F001). "Pseudothalidomide" nomenclature reflects phenotypic resemblance to thalidomide embryopathy, **not** shared environmental etiology.

### 6. Mechanism / Pathophysiology

**Causal chain (initiating lesion → clinical manifestation):**

1. **Biallelic LoF mutation in *ESCO2*** (predominantly truncating) **results in** loss of ESCO2 protein / its zinc-finger–Gcn5-like acetyltransferase activity (F001, F008).
2. Loss of ESCO2 **leads to** failure to **acetylate cohesin subunit SMC3** during S phase (F008).
3. Unacetylated cohesin **results in** defective establishment of **sister-chromatid cohesion**, especially at heterochromatic centromeric regions (F008).
4. Defective centromeric cohesion **manifests cytogenetically as** premature centromere separation (PCS) and heterochromatin repulsion (HR), plus chromosome breaks (F003).
5. From steps 3–4, the mechanism **branches** into four downstream arms:
   - **5a — Mitotic failure/apoptosis:** cohesion defects **lead to** mitotic errors and **apoptosis** of rapidly proliferating embryonic progenitors, causing tissue hypoplasia (limbs, craniofacies) (F004).
   - **5b — DNA-damage/redox stress:** cohesion/ESCO2 loss **results in** elevated redox stress, impaired oxidative-DNA-damage repair, and checkpoint hyperactivation (F005).
   - **5c — Nucleolar/translational failure:** ESCO2 loss **leads to** nucleolar fragmentation, impaired ribosome biogenesis, and **depressed mTORC1-dependent translation**, reducing protein-synthesis capacity needed for growth (F006).
   - **5d — Transcriptional/ubiquitin-ligase dysregulation:** cohesin-dependent gene regulation is perturbed, including **CRL4 (DDB1) ubiquitin-ligase** signaling downstream of Esco2/cohesin (PMID:34989322, 40396618).
6. These branches **converge to produce** the clinical triad — symmetric limb reduction (tetraphocomelia), pre/postnatal growth retardation, and craniofacial anomalies — with variable microcephaly, intellectual disability, and organ malformations (F004, F006, F007).

*Demonstrated vs inferred:* Steps 1–4 and 5a–5c are **demonstrated** in patient cells and/or animal/yeast models. The precise quantitative contribution of each branch to specific human phenotypes, and step 5d's role in humans, remain **inferred** from model organisms.

**Molecular pathways:** cohesin/sister-chromatid-cohesion pathway; **mTORC1/TOR signaling** (F006); CRL4 ubiquitin-ligase pathway. **Cellular processes:** cell cycle/mitosis (GO:0007049), apoptosis (GO:0006915), ribosome biogenesis (GO:0042254), DNA repair (GO:0006281), oxidative-stress response (GO:0006979). **Protein dysfunction:** loss of ESCO2 acetyltransferase function; loss of SMC3 acetylation (F008). **Subcellular compartments:** nucleus, **nucleolus (GO:0005730)**, chromosome/centromere, cohesin complex (GO:0008278). **Cell types (CL):** proliferating embryonic progenitors — e.g., limb-bud mesenchymal cells, cranial neural-crest–derived cells.

### 7. Anatomical Structures Affected

- **Organ/system level:** limbs (musculoskeletal) — primary; craniofacial skeleton; CNS (microcephaly, intellectual disability); frequently heart, kidney, genitalia. Systems: **musculoskeletal, nervous, cardiovascular, genitourinary, craniofacial**.
- **Tissue/cell level:** connective/skeletal tissue (bone, cartilage), rapidly dividing progenitor/mesenchymal cells, cranial neural-crest derivatives.
- **Subcellular level:** **nucleolus (GO:0005730)**, nucleus (GO:0005634), chromosome/centromere (GO:0000775), cohesin complex (GO:0008278).
- **Localization/lateralization:** malformations are **bilateral and symmetric** (defining feature; HP:0009829).
- **UBERON suggestions:** UBERON:0002101 (limb), UBERON:0001456 (face), UBERON:0000955 (brain), UBERON:0002113 (kidney), UBERON:0000948 (heart).

### 8. Temporal Development

- **Onset:** **congenital/prenatal**; malformations arise during embryogenesis; growth restriction detectable in utero.
- **Progression:** structural anomalies are **static/non-progressive** after birth, but severe forms carry high perinatal mortality; growth deficiency persists postnatally.
- **Duration/course:** in survivors (milder/SC phocomelia end), a **chronic lifelong** disability. **Critical period:** the vulnerable window is **embryonic organogenesis and limb development** — there is no postnatal window to reverse structural malformations, underscoring prenatal counseling/diagnosis.

### 9. Inheritance and Population

- **Inheritance:** **Autosomal recessive** (F001, F002). Consanguinity increases risk (F007).
- **Penetrance/expressivity:** high penetrance for biallelic LoF; **highly variable expressivity with NO genotype–phenotype correlation** (F002, F007).
- **Epidemiology:** very rare; **~150 reported cases** historically (Orphanet <1/1,000,000). No reliable incidence figures.
- **Founder effects / carrier frequency:** not well quantified; recurrent exon-3 alleles seen in consanguineous cohorts (F007).
- **Sex ratio:** autosomal — **no sex predilection** (M:F ≈ 1:1).
- **Geographic distribution:** worldwide; over-representation of homozygous cases in high-consanguinity populations (e.g., North Africa/Middle East).

### 10. Diagnostics

- **Cytogenetics (hallmark):** metaphase analysis showing **PCS and HR** ("railroad tracks"/centromeric puffing) by Giemsa/DAPI/C-banding; chromosome breaks (F003). Low-cost, highly specific.
- **Molecular genetic testing:** **single-gene *ESCO2* sequencing** confirmatory (F001, F007); gene panels or **WES/WGS** for atypical presentations. Targeted variant testing enables carrier and prenatal diagnosis in known families.
- **Imaging:** **fetal ultrasound** with long-bone measurement detects limb reduction prenatally (F007); postnatal radiographs characterize skeletal defects.
- **Prenatal diagnosis:** feasible by **serial fetal ultrasound** and molecular testing (CVS/amniocentesis) or PCS/HR analysis of fetal cells (F007).
- **Differential diagnosis:** thalidomide embryopathy, Cornelia de Lange syndrome (allied cohesinopathy), TAR syndrome, Baller–Gerold syndrome, Fanconi anemia, and other phocomelia/limb-reduction syndromes — distinguished by the pathognomonic **PCS/HR cytogenetic signature** and *ESCO2* genotype.
- **Screening:** no population newborn screening; **cascade carrier screening** in affected families and consanguineous couples is appropriate.

### 11. Outcome / Prognosis

- **Survival/mortality:** bimodal. **Severe forms** → intrauterine death, stillbirth, or early neonatal/infant mortality. **Milder forms (SC phocomelia)** → survival into childhood/adulthood.
- **Morbidity/function:** major mobility disability from limb reduction; variable intellectual disability; feeding/airway issues from craniofacial anomalies.
- **Complications:** organ malformations (cardiac, renal, genital), infection risk, clefting complications.
- **Prognostic factors:** overall severity/extent of malformations and major organ anomalies predict survival; **no molecular prognostic biomarker** (consistent with no genotype–phenotype correlation, F002). Formal survival/QoL registry data are **not available**.

### 12. Treatment

**No curative or disease-modifying approved therapy exists.** Management is **supportive, reconstructive, and rehabilitative**:

- **Surgical/interventional:** orthopedic and reconstructive surgery for limb/craniofacial anomalies; cleft repair; correction of associated organ malformations. (NCIT: reconstructive surgical procedure.)
- **Supportive/rehabilitative:** prosthetics/orthotics, physical/occupational therapy, speech therapy, nutritional support, developmental/educational support. (NCIT: physical therapy; occupational therapy.)
- **Mechanism-based experimental lead:** **L-leucine** (CHEBI:15603), an mTORC1 stimulator, partially rescues translation, cell division, and development in RBS cell and zebrafish models (F006) — a preclinical lead, **not** an established human therapy. Antioxidants are a further experimental concept from yeast models (F005). Chemical chaperones (e.g., sorbitol) and proteostasis modulators have been explored in yeast RBS models (PMID:40668332).
- **Pharmacogenomics:** not applicable.

### 13. Prevention

- **Primary prevention:** **genetic counseling** for at-risk/consanguineous couples; **carrier screening**; where desired, **preimplantation genetic diagnosis (PGD)** or **prenatal diagnosis** (F007) to inform reproductive decisions.
- **Secondary prevention:** prenatal ultrasound surveillance in known families for early detection (F007).
- **Tertiary prevention:** multidisciplinary management to prevent complications in survivors.
- No immunization, behavioral, or public-health environmental interventions apply (non-environmental etiology).

### 14. Other Species / Natural Disease

- **Taxonomy of models:** *Danio rerio* (zebrafish, NCBI:txid7955); *Saccharomyces cerevisiae* (NCBI:txid4932). **Orthologous genes:** zebrafish *esco2*; yeast *ECO1/CTF7*; human *ESCO2* (NCBI Gene 157570). Paralog *ESCO1*.
- **Natural disease in animals:** no well-documented naturally occurring ESCO2 disorder in companion animals/wildlife is established (no prominent OMIA natural RBS analog). Not zoonotic or transmissible.
- **Comparative/evolutionary:** the cohesin acetylation mechanism (Eco1→Esco2) is **deeply conserved** from yeast to humans, which is why yeast and zebrafish faithfully model core RBS biology (F004, F005, F006, F008).

### 15. Model Organisms

| Model | Type | Recapitulation | Key use | Limitation |
|---|---|---|---|---|
| **Zebrafish** *esco2* knockdown | Vertebrate, in vivo | Mitotic defects, craniofacial anomalies, limb truncations (F004); L-leucine rescue (F006) | Developmental mechanism, therapy testing | Skeletal anatomy differs from human |
| **Yeast** *eco1* mutants (e.g., eco1W216G) | Unicellular | Redox/DNA-damage stress (F005), translational defects, condensation | Molecular mechanism; antioxidant/chaperone screening | Lacks multicellular/developmental phenotypes |
| **Patient-derived cells** | In vitro (human) | Nucleolar fragmentation, translation defects, PCS/HR (F003, F006) | Cytogenetic diagnosis, translation studies | Cell-autonomous only |
| **ESCO1 crystal structure** | Structural/computational | Defines Gcn5-like acetyltransferase + zinc finger (F008) | Structure–function of catalysis/SMC3 binding | Paralog (ESCO1), not ESCO2 directly |

**Resources:** ZFIN (zebrafish), SGD (yeast), PDB (structures), Cellosaurus (patient cell lines).

---

## Mechanistic Model / Interpretation

```
   ESCO2 biallelic LoF mutation (8p21.1; mostly truncating, exon-3 frameshifts)
                         │
                         ▼
     Loss of ESCO2 zinc-finger/Gcn5-like acetyltransferase activity
                         │
                         ▼
        Failure to acetylate cohesin subunit SMC3 (S phase)
                         │
                         ▼
     Defective sister-chromatid cohesion at centromeric heterochromatin
                         │
        └── cytogenetic readout: PCS + HR + chromosome breaks
                         │
      ┌──────────────────┼───────────────────┬────────────────────┐
      ▼                  ▼                   ▼                    ▼
 (5a) Mitotic       (5b) Redox stress   (5c) Nucleolar       (5d) Cohesin-
 failure &          + impaired DNA-      fragmentation →      dependent
 APOPTOSIS of       repair + checkpoint  ↓ribosome biogenesis transcription
 progenitors        hyperactivation      → ↓mTORC1 translation dysregulation
      │                  │                   │ (rescued by         (CRL4/DDB1)
      │                  │                   │  L-leucine)            │
      └──────────────────┴─────────┬─────────┴────────────────────────┘
                                    ▼
        Tissue hypoplasia / disrupted growth & morphogenesis
                                    ▼
   Symmetric limb reduction (tetraphocomelia) + pre/postnatal growth
   retardation + craniofacial anomalies (± microcephaly, ID, organ defects)
```

The unifying interpretation is that RBS is a **cohesinopathy of establishment**: the primary lesion is not the cohesin ring itself but its **S-phase activation via SMC3 acetylation**. Because ESCO2 is essential for faithful, rapid cell division, the tissues most dependent on high-throughput proliferation during embryogenesis — limb buds, craniofacial primordia, and the growing soma — are the most severely affected. The **convergence of four downstream branches** (apoptosis, DNA-damage/redox stress, translational collapse, transcriptional dysregulation) explains both the **severity** and the **pleiotropy** of the phenotype, while the fact that all four stem from a single upstream LoF explains the **lack of genotype–phenotype correlation** (F002): once ESCO2 is non-functional, downstream damage is governed by stochastic and modifier-dependent factors rather than the identity of the truncating allele.

---

## Evidence Base

| PMID | Title (abbrev.) | Evidence type | Supports |
|---|---|---|---|
| [16380922](https://pubmed.ncbi.nlm.nih.gov/16380922/) | *Inactivating mutations in ESCO2 cause SC phocomelia and Roberts syndrome* | Human genetics | F001, F002 — ESCO2/8p21.1; truncating LoF; allelism; no G–P correlation |
| [32783269](https://pubmed.ncbi.nlm.nih.gov/32783269/) | *Roberts syndrome... novel homozygous splice variant in ESCO2* | Human clinical | F001, F003 — biallelic LoF; PCS/HR/breaks |
| [30204960](https://pubmed.ncbi.nlm.nih.gov/30204960/) | *Roberts syndrome in 8 Egyptian patients* | Human cohort | F002, F003 — cytogenetics; no G–P correlation |
| [21637801](https://pubmed.ncbi.nlm.nih.gov/21637801/) | *A zebrafish model of Roberts syndrome* | Model organism | F004 — cell cycle/apoptosis; phenotype recapitulation |
| [34897432](https://pubmed.ncbi.nlm.nih.gov/34897432/) | *Genetically induced redox stress in a yeast model for RBS* | Model organism | F005 — redox stress; antioxidant rescue |
| [26729373](https://pubmed.ncbi.nlm.nih.gov/26729373/) | *Improved transcription/translation with L-leucine in RBS* | In vitro + model | F006 — mTORC1/translation; L-leucine rescue |
| [25378554](https://pubmed.ncbi.nlm.nih.gov/25378554/) | *L-leucine rescues translational/developmental defects (CdLS/RBS)* | In vitro + model | F006 — nucleolar fragmentation; ribosome biogenesis |
| [26710928](https://pubmed.ncbi.nlm.nih.gov/26710928/) | *Expanding the mutation and clinical spectrum of RBS* | Human cohort | F007 — exon-3 frameshifts; prenatal US; variable expressivity |
| [27803161](https://pubmed.ncbi.nlm.nih.gov/27803161/) | *Molecular basis for cohesin acetylation by ESCO1* | Structural | F008 — Gcn5-like AT domain; SMC3 binding; disease missense |
| [34989322](https://pubmed.ncbi.nlm.nih.gov/34989322/) | *Esco2 and cohesin regulate CRL4 ubiquitin ligase* | Model organism | Mechanism branch 5d — CRL4 pathway |
| [40396618](https://pubmed.ncbi.nlm.nih.gov/40396618/) | *Protein turnover downstream of Nipbl/CRL4 axis in zebrafish* | Model organism | Branch 5d — CRL4/DDB1 substrate accumulation |
| [31935221](https://pubmed.ncbi.nlm.nih.gov/31935221/) | *Non-redundant roles of DDX11, ESCO1, ESCO2 in cohesion* | In vitro | Modifier/interactor context (DDX11) |
| [40668332](https://pubmed.ncbi.nlm.nih.gov/40668332/) | *Cohesin function altered by chemical chaperones* | Model organism | Experimental therapeutics (sorbitol/proteostasis) |
| [33382686](https://pubmed.ncbi.nlm.nih.gov/33382686/) | *Ever-changing landscape in RBS biology: macromolecular damage* | Review | Integrative "macromolecular damage" model |
| [31516082](https://pubmed.ncbi.nlm.nih.gov/31516082/) | *Expanding phenotypes of cohesinopathies* | Review | Positions RBS among cohesinopathies |
| [35495290](https://pubmed.ncbi.nlm.nih.gov/35495290/) | *Roberts syndrome with tetraphocomelia: case report* | Human clinical | Severe/prenatal-lethal end of the spectrum |

**Consistency:** The findings are mutually reinforcing across four evidence tiers — human genetics/clinical (F001–F003, F007), model organism in vivo (F004–F006), yeast molecular (F005), and structural biology (F008). No finding was contradicted by another; the literature is convergent rather than conflicting.

---

## Limitations and Knowledge Gaps

1. **No quantitative human epidemiology:** prevalence/incidence, sex/age distributions, and survival statistics are not rigorously established given rarity (~150 reported cases).
2. **No genotype–phenotype predictor:** the striking absence of correlation (F002) means severity cannot be predicted molecularly, limiting prenatal prognostication.
3. **Human validation of mechanistic branches is incomplete:** the redox-stress (yeast, F005), CRL4 (zebrafish/yeast, 5d), and even mTORC1/translation arms (F006) are strongest in model systems; their precise contribution to specific human malformations is inferred.
4. **Therapeutics are preclinical only:** L-leucine and antioxidant/chemical-chaperone strategies have not entered validated human trials for RBS.
5. **No modifier genes or epigenetic signature identified in humans**, leaving expressivity unexplained.
6. **Structural data are from the ESCO1 paralog** (F008), not ESCO2 directly; residue-level extrapolation to ESCO2 missense alleles is approximate.
7. **No documented natural animal disease / veterinary model** beyond engineered systems.

---

## Proposed Follow-up Experiments / Actions

1. **Human natural-history registry:** aggregate cases to derive prevalence, survival curves, and organ-involvement frequencies; power genotype–phenotype re-analysis including modifiers.
2. **ESCO2-specific structural study:** solve the ESCO2 (not ESCO1) acetyltransferase–SMC3 complex to classify RBS missense VUS by catalytic impact.
3. **Isogenic human iPSC/organoid models** (limb-bud, cranial neural crest, cerebral organoids) with patient *ESCO2* alleles to quantify each mechanistic branch (apoptosis vs translation vs redox vs CRL4) in relevant human cell types.
4. **Therapeutic testing:** rigorously evaluate **L-leucine** (and antioxidant combinations) in patient organoids and, if warranted, a mechanism-based early-phase clinical study; explore chemical chaperones/proteostasis modulators active in yeast.
5. **Multi-omics profiling** (transcriptomics + proteomics + ribosome profiling) of RBS patient cells to map the ESCO2-loss signature and identify actionable nodes (mTORC1, CRL4/DDB1 substrates such as pparαa).
6. **Modifier screens** (CRISPR) in RBS cell models — building on DDX11/WAPL/PDS5/RAD61 interactions — to find genetic buffers of the cohesion/translation defect.
7. **Prenatal diagnostic standardization:** formalize a serial-ultrasound + molecular pathway (validated in F007) into clinical guidance for at-risk consanguineous families.

---

*Report compiled from 8 confirmed findings and 21 reviewed papers across 5 investigation iterations. Evidence tiers: human clinical/genetic, model organism (zebrafish, yeast), in vitro (patient cells), and computational/structural.*


## Artifacts

- [OpenScientist final report](Roberts_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Roberts_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0rc1.

| Outcome | Count |
| --- | --- |
| References checked | 16 |
| Resolved | 16 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 16 |
| On topic | 15 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 38 |
| Resolved | 35 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 3 |
| Terms whose name was checked | 21 |
| Terms named correctly | 15 |
| Terms named as a **different** term | 5 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `CHEBI:15603` (2 mentions) - the report calls it "L-leucine", "Mechanism-based experimental lead:** **L-leucine"; CHEBI calls it **L-leucine**
- `HP:0000252` (1 mention) - the report calls it "Common"; HP calls it **Microcephaly**
- `HP:0001249` (1 mention) - the report calls it "Mild–severe, variable"; HP calls it **Intellectual disability**
- `HP:0012165` (1 mention) - the report calls it "Common"; HP calls it **Oligodactyly**
- `HP:0003826` (1 mention) - the report calls it "Severe forms"; HP calls it **Stillbirth**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `GO:0005730` (3 mentions) - the report calls it "nucleolus", "Subcellular level:** **nucleolus"; GO calls it **nucleolus**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `GO:0005730` - called "nucleolus", "Subcellular level:** **nucleolus"
- `CHEBI:15603` - called "L-leucine", "Mechanism-based experimental lead:** **L-leucine"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`, `OMIM`.